Answers are grounded in this paper and cite their sources.
Introduction Antimicrobial resistance poses a substantial threat to global healthcare particularly in immunocompromised individuals. Burkholderia cenocepacia is a clinically important opportunistic bacterium responsible for persistent respiratory infections in cystic fibrosis patients. Its intrinsic antimicrobial resistance and ability to form biofilms make conventional treatment ineffective. Therefore, targeting virulence-associated quorum sensing pathway represents an alternative anti-virulence strategy to reduce pathogenicity without directly imposing bactericidal pressure. Importantly, CepI , an autoinducer synthase involved in acyl-homoserine lactone biosynthesis, serves as a promising molecular target for disrupting quorum sensing mediated pathogenicity. Methods The present study combines randomized-SMILES augmentation, LSTM-based molecular generation, machine-learning-aided drug repurposing and structure-based validation to identify potential CepI -targeting candidates. Model robustness was evaluated using scaffold-aware, y-randomization, provenance-control and cross-provenance. The optimized model was applied to the DrugBank library, followed by applicability-domain assessment using Mahalanobis distance, k-nearest-neighbor analysis and principal component analysis. Prioritized candidates were further evaluated by docking, MM-GBSA, ADMET analysis and triplicate molecular dynamics simulations. Results and discussion Among the evaluated classifiers, the Extra Trees model showed the best 10-fold cross-validation performance, with a ROC-AUC of 0.992 ± 0.025. In contrast, 100-iteration Y-randomization produced a mean ROC-AUC of 0.481 ± 0.084 (maximum = 0.559), compared with 0.99 for the original model (p = 0.0099). The near-chance performance under randomized labels provided evidence against a simple chance-label explanation. Provenance-control analyses indicated that the classification signal was not explained solely by a simple literature-versus-LSTM source label, although residual provenance and chemical-space bias cannot be completely excluded. Integration of the activity-probability threshold and applicability-domain criteria narrowed the DrugBank screening set to 115 compounds for structure-based analysis. Among these, DB12364 (betrixaban) was prioritized based on its predicted activity, applicability-domain assessment, docking, MM-GBSA and molecular dynamics results, and is proposed as a computationally prioritized candidate for experimental evaluation as a potential CepI -targeting compound against B. cenocepacia .
No takes yet. Share an insight, caveat, or question.
Magizhvannan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: